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Amir Lerman, MD, FACC,* Sundeep Khosla, MD†
Rochester, Minnesota
Objectives This study was designed to test whether patients with coronary atherosclerosis have increases in circulating en-
dothelial progenitor cells (EPCs) expressing an osteogenic phenotype.
Background Increasing evidence indicates a link between bone and the vasculature, and bone marrow and circulating osteo-
genic cells have been identified by staining for the osteoblastic marker, osteocalcin (OCN). Endothelial progeni-
tor cells contribute to vascular repair, but repair of vascular injury may result in calcification. Using cell surface
markers (CD34, CD133, kinase insert domain receptor [KDR]) to identify EPCs, we examined whether patients
with coronary atherosclerosis had increases in the percentage of EPCs expressing OCN.
Methods We studied 72 patients undergoing invasive coronary assessment: control patients (normal coronary arteries and no
endothelial dysfunction, n 21) versus 2 groups with coronary atherosclerosis—early coronary atherosclerosis (nor-
mal coronary arteries but with endothelial dysfunction, n 22) and late coronary atherosclerosis (severe, multivessel
coronary artery disease, n  29). Peripheral blood mononuclear cells were analyzed using flow cytometry.
Results Compared with control patients, patients with early or late coronary atherosclerosis had significant increases
(2-fold) in the percentage of CD34/KDR and CD34/CD133/KDR cells costaining for OCN. Even larger
increases were noted in the early and late coronary atherosclerosis patients in the percentage of CD34/
CD133/KDR cells costaining for OCN (5- and 2-fold, p  0.001 and 0.05, respectively).
Conclusions A higher percentage of EPCs express OCN in patients with coronary atherosclerosis compared with subjects
with normal endothelial function and no structural coronary artery disease. These findings have potential
implications for the mechanisms of vascular calcification and for the development of novel markers for coronary
atherosclerosis. (J Am Coll Cardiol 2008;52:1314–25) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.019b
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dhere is increasing evidence for a link between bone
etabolism and the vasculature. Thus, elderly women with
steoporosis (1) or with high bone turnover (2) have
ncreased cardiovascular mortality. In addition, mice with
eletion of osteoprotegerin (OPG), which binds and neu-
ralizes the key osteoclastogenic factor, receptor activator of
uclear factor kappa B ligand (RANKL), have not only
evere osteoporosis and a marked increase in bone turnover
ut also diffuse vascular calcification (3). Moreover, it is now
ecognized that vascular calcification is not simply a dystro-
hic calcifying process, but rather it involves active bone
ormation that recapitulates the normal sequence of osteo-
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ccepted July 21, 2008.last development and activity on bone surfaces (4,5). These
ndings collectively suggest that changes in bone turnover
ffect the vasculature, although the possible mechanisms of
his are unclear.
Potential candidates for providing a link between bone
etabolism and the vasculature are endothelial progenitor
ells (EPCs) that reside, at least in part, in bone marrow, are
obilized in response to vascular injury, and contribute to
ascular repair (6). Although there is ongoing controversy
egarding the true identity of EPCs (6), cell surface expres-
ion of CD34, CD133, and vascular endothelial growth
actor receptor 2/kinase insert domain receptor (KDR) has
een used to define populations of circulating cells that
nclude cells participating in the response to vascular injury
6,7). In addition, recent work has suggested that expression
f these markers may be used to classify CD34 cells as less
ifferentiated (CD34/CD133/KDR) versus relatively
ore differentiated (CD34/CD133/KDR) EPCs (6–8).
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October 14, 2008:1314–25 Osteocalcin and Endothelial ProgenitorsIn addition to EPCs, osteoprogenitor cells also reside in
he bone marrow, and studies by Friedenstein et al. (9)
stablished almost 40 years ago that the bone marrow
troma contains plastic adherent cells that can give rise to a
road spectrum of fully differentiated connective tissues,
ncluding osteoblasts. Concurrent with this work, however,
ong et al. (10,11) identified, over a decade ago, a nonad-
erent population of cells in bone marrow with osteogenic
otential. These investigators used flow cytometry and
agnetic activated cell sorting with an anti-osteocalcin
OCN) antibody to isolate osteoprogenitor cells that ex-
ressed bone-related proteins and were capable of mineral-
zation in vitro (10–13). Reasoning that these nonadherent
steogenic cells likely accessed the peripheral circulation, our
roup used identical methods to characterize OCN cells in
eripheral blood that expressed osteoblastic markers and were
apable of forming mineralized nodules in vitro and bone in
ivo (14,15).
Although endothelial and osteoblastic cells have tradi-
ionally been believed to derive from distinct progenitor
opulations, there is increasing evidence for overlap between
hese lineages. In fact, the STRO-1 antibody, which is
idely used to identify mesenchymal stem cells in bone
arrow and other tissues, was originally derived by immu-
izing mice with purified human CD34 cells (16). More-
ver, human bone marrow CD34 cells can differentiate
nto osteoblastic cells capable of forming mineralized nod-
les in vitro (17), and Tondreau et al. (18) have found that
D133 cells from human bone marrow, umbilical cord
lood, or peripheral blood from granulocyte colony-
timulating factor–treated donors are enriched for mesen-
hymal stem cells capable of differentiating into osteoblasts
18). Recent studies using single cell reverse-transcriptase
olymerase chain reaction have also demonstrated that
20% of human peripheral blood CD34 cells express the
essenger ribonucleic acid (mRNA) for OCN (19). In
ddition, when infused into immunocompromised rats fol-
owing femur fractures, these cells can localize to the
racture site and differentiate into endothelial cells as well as
steoblasts and enhance fracture healing (19).
Given this potential overlap between endothelial and
steoblastic lineages, in the current study, we tested the
ypothesis that there is an increased percentage of circulat-
ng EPCs expressing an osteogenic phenotype, as assessed
y staining for OCN (10–15), in patients with early or
stablished coronary atherosclerosis. Our findings suggest a
ovel link between bone metabolism and the vasculature
nd may also help define new diagnostic approaches for
oronary atherosclerosis.
ethods
tudy subjects. The study was approved by the Institu-
ional Review Board of Mayo Foundation, and all study
ubjects provided written, informed consent. A total of 72
atients who were undergoing coronary angiography and soronary endothelial function
esting for clinical purposes, and
et the criteria outlined here for
nclusion into the 3 study groups,
ere recruited. Patients with
cute coronary syndromes (un-
table angina or acute myocardial
nfarction), heart failure (ejection
raction 50%), or severe renal
r liver disease were excluded.
he Framingham risk score was
alculated as previously described
20). The 3 groups were defined
s follows: control, patients with-
ut significant structural coro-
ary lesions on angiography
30% stenosis) and normal en-
othelial function, as assessed by
ntracoronary acetylcholine chal-
enge (see the following section)
n  21); early coronary athero-
clerosis (ECA), defined by the
bsence of significant structural
oronary lesions on angiography
ut with abnormal endothelial
unction (n  22); and late cor-
nary atherosclerosis (LCA), de-
ned as patients with severe,
ultivessel coronary artery dis-
ase (CAD) (50% stenosis in 2
r more major epicardial arteries)
n  29).
oronary angiography and in-
asive endothelial function
esting. Patients underwent cor-
nary angiography using stan-
ard clinical protocols. Arterial blood (20 ml) was drawn
rom the aortic catheter prior to cardiac catheterization for
ow cytometry and biochemical analyses. After diagnos-
ic angiography, subjects without significant structural
oronary lesions underwent assessment of endothelium-
ependent coronary vasoreactivity, as previously de-
cribed (21–24). In brief, a Doppler guidewire (Flowire,
olcano Corporation, San Diego, California) within a
oronary-infusion catheter (Ultrafuse, SciMed Life Sys-
em, Maple Grove, Minnesota) was positioned into the
id-portion of the left anterior descending coronary
rtery. Acetylcholine at increasing concentrations was
nfused into the left anterior descending coronary artery
o assess endothelium-dependent vasoreactivity. Hemo-
ynamic data, Doppler measurements, and a coronary
ngiogram were obtained after each infusion. Coronary
rtery diameter was measured by an independent inves-
igator in the segment 5-mm distal to the tip of the
oppler wire using a computer-based image analysis
Abbreviations
and Acronyms
APV  average peak
velocity
CAD  coronary artery
disease
ECA  early coronary
atherosclerosis
ELISA  enzyme-linked
immunosorbent assay
EPC  endothelial
progenitor cell
hMSC  human bone
marrow stromal cell
hs-CRP  high sensitivity
C-reactive protein
KDR  kinase insert
domain receptor
LCA  late coronary
atherosclerosis
MACS  magnetic
activated cell sorting
MGP  matrix Gla protein
mRNA  messenger
ribonucleic acid
OCN  osteocalcin
OPG  osteoprotegerin
OPN  osteopontin
PBMNC  peripheral blood
mononuclear cell
RANKL  receptor
activator of nuclear factor
kappa B ligand
ROC  receiver-operator
characteristicystem. Average peak velocity (APV) was derived from
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Osteocalcin and Endothelial Progenitors October 14, 2008:1314–25he Doppler flow velocity spectra and coronary blood flow
as determined as:  (coronary artery diameter/2)2 
APV/2). As previously described, microvascular endo-
helial dysfunction was defined as an increase in coronary
lood flow of 50% and epicardial endothelial dysfunc-
ion was defined as a decrease in epicardial coronary
rtery diameter of 20% in response to the maximal dose
f acetylcholine (104 mol/l) (21–24). Endothelium-
ndependent microvascular function was determined by
he coronary flow reserve, which is the ratio of the APV
t maximal hyperemia (induced by intracoronary adeno-
ine [18 to 60 g]) to the APV at baseline.
low cytometry. Peripheral blood mononuclear cells
PBMNCs) were isolated using a Ficoll density gradient,
nd immunofluorescent cell staining was performed using
he following fluorescent conjugated antibodies: CD34-
erCP Cy 5.5 (Becton-Dickinson, Franklin Lakes, New
ersey), CD133-phycoerythrin (Miltenyi Biotec GmbH,
ergisch Gladbach, Germany), and KDR-allophycocyanin
R & D Systems, Minneapolis, Minnesota) and the appro-
riate isotype controls. In addition, OCN cells were
dentified using an antihuman OCN antibody (Santa Cruz
iotechnology, Santa Cruz, California) and a fluorescein
sothiocyanate secondary antibody (Jackson Immuno-
esearch, West Grove, Pennsylvania), as previously described
14,15). Cell fluorescence was measured immediately after
taining (FACSCalibur, Becton Dickinson) and data were
nalyzed using CellQuest software (Becton Dickinson).
onfocal microscopy. For confocal microscopy, cells were
tained for OCN–fluorescein isothiocyanate and CD34-
erCP Cy 5.5 and isolated by magnetic activated cell sorting
MACS) (AutoMACS, Miltenyi Biotec GmbH) with the
ppropriate magnetic beads. The cells were then costained
ith the CD133-phycoerythrin and KDR-allophycocyanin
ntibodies. Following fixation, the cells were mounted in
roLong Gold antifade reagent with 4,6-diamino-2-
henylindole, DAPI (Invitrogen, Carlsbad, California), to
tain the nucleus. Samples were then examined on an
SM510 confocal laser scanning microscope (Carl Zeiss
nc., Maple Grove, Minnesota).
ell culture. The CD34 cells isolated by MACS or
uman bone marrow stromal cells (hMSCs) (Lonza, Basel,
witzerland) were cultured in uncoated plastic culture plates
n regular culture media (alpha minimal essential medium,
0% heat-inactivated fetal bovine serum, 1% penicillin/
treptomycin/amphotericin B [all from GIBCO/Invitrogen
orporation, Carlsbad, California]) containing an addi-
ional 5 mmol/l Ca2 for the first 5 days. Subsequently, the
edium was changed to osteoblast differentiation medium
alpha minimal essential medium, 10% heat-inactivated fetal
ovine serum, 1% penicillin/streptomycin/amphotericin B
lus 50 g/ml ascorbic acid phosphate magnesium salt
-hydrate [Wako, Richmond, Virginia], 10 mmol/l beta-
lycerophosphate, 108 mol/l 1,25-dihydroxyvitamin D3,
08 mol/l dexamethasone [Sigma-Aldrich, St. Louis, Mis-
ouri]) for an additional 7 days. The mineralization assay kas done using MACS-sorted CD34 cells and unsorted
ost-Ficoll PBMNCs, which were cultured in uncoated
lastic culture plates in regular culture media for 2 days and
hen were either maintained in regular culture medium or
ere changed to regular culture medium containing an
dditional 2.1 mmol/l Ca2 for 5 days (days 3 to 7) of
ulture. Subsequently, the Ca2 was removed and the cells
ere cultured in osteoblast differentiation medium (as de-
cribed before) for an additional 21 days (days 8 to 28) and
he presence of mineralization determined by alizarin red
nd von Kossa staining.
ssessment of gene expression in CD34 cells. The
D34 cells were isolated using MACS, as described
arlier. Total ribonucleic acid (RNA) from CD34 cells and
ndifferentiated hMSCs (Lonza) was isolated using spin
olumns (Micro columns, Qiagen, Valencia, California)
ollowed by a deoxyribonuclease digestion. Because the
verall number of the CD34 cells was limited and there-
ore the yield of total RNA was low, we used the WT-
vationPico RNA amplification system (NuGEN Tech-
ologies Inc., San Carlos, California) to synthesize
icrograms quantities of amplified complementary deoxyri-
onucleic acid starting with total RNA input amounts of 50
g for all the samples. In this linear amplification system,
he relative representation of each transcript species in the
riginal sample is maintained during and after amplifica-
ion. The pre-amplified complementary deoxyribonucleic
cid was then used in quantitative polymerase chain reaction
nalyses using primer pairs for a panel of bone- and stem
ell–related genes (Table 1). Normalization of the samples
as performed using the geNorm method (25,26), which
etermines the most stable housekeeping genes within the
xperiment. Further analysis was performed by calculating
he difference in cycle threshold (CT) values between the
ample and the geometric mean cycle threshold of geNorm
elected housekeeping genes. The expression level for each
ndividual gene was determined by 2CT.
iochemical assays. Serum lipids were measured using
nzymatic colorimetry and low-density lipoprotein choles-
erol calculated from these parameters. High sensitivity
-reactive protein (hs-CRP) levels were measured using a
atex particle-enhanced immunoturbidimetric assay on a
itachi 912 automated analyzer (Hitachi America Ltd.,
arrytown, New York). Serum creatinine was measured
sing an enzymatic colorimetric assay (Roche Diagnostics,
ndianapolis, Indiana) and glomerular filtration rate (GFR)
as estimated using the isotope dilution–mass spectrometer
raceable MDRD (Modification of Diet in Renal Disease)
tudy equation: estimated GFR (ml/min/1.73 m2)  175 
erum creatinine (1.154)  age (0.203)  (0.742 if
emale)  (1.210 if African American).
The RANKL was measured using the ampli-sRANKL
nzyme-linked immunosorbent assay (ELISA) (ALPCO
iagnostics, Salem, New Hampshire). Ampli-sRANKL
as increased sensitivity compared with standard ELISA
its, because it uses a reduced nicotinamide adenine dinu-
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October 14, 2008:1314–25 Osteocalcin and Endothelial Progenitorsleotide phosphate-based enhancement system. Osteopro-
egerin and matrix Gla protein (MGP) were also measured
sing ELISAs (ALPCO Diagnostics). The interassay coef-
cients of variation for the RANKL, OPG, and MGPs
LISAs were 6%, 8%, and 9%, respectively.
tatistical analyses. Pre-specified comparisons between
he ECA or LCA patients and control subjects were made
sing the Wilcoxon rank sum test for continuous variables
nd the Fisher exact test for categorical variables. Because
ome of these data were not normally distributed, they are
resented as median (interquartile [25th to 75th percentile]
ange). Spearman correlations were used to describe rela-
ionships between the cell populations with circulating
ANKL, OPG, and MGP levels. Logistic regression mod-
ls following logarithmic (base 2) transformation, where
ppropriate, of the CD34/CD133/KDR/OCN and
he percentage of CD34/CD133/KDR cells costaining
or OCN or of hs-CRP were used to assess the ability of
hese variables to predict ECA following adjustment for age
nd gender. Model assumptions and conclusions were
hecked. Receiver-operator characteristic (ROC) curve
nalysis was used to describe the ability of the CD34/
D133/KDR/OCN and the percentage of CD34/
D133/KDR cells costaining for OCN or of hs-CRP to
redict ECA, and the areas under the ROCs were compared
sing a nonparametric test (27). The gene expression data
re presented as mean 	 standard error of the mean. For
omparison with hMSCs, the expression of each gene was
ormalized to the level of expression in the hMSCs and
ompared with 1.0 using a 1-sample t test. Differences
etween freshly isolated and cultured CD34 cells were
nalyzed using a 2-sample t test. Any p values 0.05 were
ene Identification and Primer Sequences
Table 1 Gene Identification and Primer Sequences
Gene ACC Number
Runx2 NM_001024630F
Beta catenin NM_001904F
BMP2 NM_001200F
Msx-2 NM_002449F
Notch1 NM_017617F
OCN NM_199173F
Alkaline phosphatase NM_000478F
Osteonectin NM_003118F
Osteopontin NM_00104058F
MGP NM_000900F
Col1 alpha1 NM_000088F
Col1 alpha2 NM_000089F
CD44 NM_000610F
Nanog NM_024865F
HIF1 alpha NM_017902F
CXCR4 NM_001008540F
CD45 NM_002838F
CD34 NM_001025109F
CC  anterior cingulate cortex; HIF  hypoxia-inducible factor; MGP  matrix Gla protein; OCN onsidered statistically significant. aesults
atient characteristics. The relevant clinical and biochem-
cal data as well as the detailed cardiac catheterization data
n the study subjects are shown in Table 2. Subjects with
CA were significantly older than the control subjects and
ere predominantly male. However, subjects with ECA had
n age and gender mix not significantly different from the
ontrol subjects. Body mass index was similar across groups,
ut a higher percentage of the LCA subjects were on statins
ompared with control subjects. The prevalence of diabetes,
ypertension, and smoking was virtually identical in the
ontrol and ECA subjects, but it was higher for all 3
arameters in the LCA compared with the control subjects.
here was no significant difference in the Framingham
core between the subjects with ECA and control subjects,
ut the score was significantly higher in the subjects with
CA as compared with the control subjects. Blood lipids
ere similar in the ECA subjects compared with the control
ubjects, with the LCA subjects having lower total and
igh-density lipoprotein cholesterol levels compared with
he control subjects. There was a nonsignificant trend for
s-CRP levels to be higher in the ECA compared with
ontrol subjects; by contrast, patients with LCA had hs-
RP levels that were significantly lower than those of
ontrol subjects. Because statin therapy is known to reduce
RP levels (28), the lower hs-CRP levels in the LCA patients
ere likely related to the fact that most of these patients were
n statin therapy. Overall, therefore, although there were
ignificant differences in the clinical characteristics of the LCA
atients compared with subjects with normal coronary endo-
helial function, the patients with coronary endothelial dys-
unction had clinical and biochemical features that were virtu-
Forward Primer Reverse Primer
AGATGGGACTGTGGTTACTG TTCCGGAGCTCAGCAGAATAA
GTCCGCATGGAAGAAATAG TGTGAACATCCCGAGCTAGGA
CCTTTTCCTCTGGCTGAT TTGACCAACGTCTGAACAATGG
ACTGCAGGAGGCAGAACTG GGAGGGCAGCATAGGTTTTG
CCAGTTTGAATGGTCAATGC CCGCAGAGGGTTGTATTGGTT
TGAGCTCAATCCGGACTGT CCGATAGGCCTCCTGAAAGC
GTTGACACCTGGAAGAGCTT CGTGCGGTTCCAGATGAAGT
ACATCGGGCCTTGCAAAT GGGAATTCGGTCAGCTCAGA
AGCATTCCGATGTGATTGA TGTGGAATTCACGGCTGACTT
TCCAAGAGAGGATCCGAGAA GCGTTCGCAAAGTCTGTAGTCA
CCCCACTCAGCCCAGTGT ACCAGACATGCCTCTTGTCCTT
TACCCAACTTGCCTTCATG TGCAGTGGTAGGTGATGTTCTGA
TCATCTTGGCATCCCTCTTG CGACTGTTGACTGCAATGCAA
AGGCAAACAACCCACTTCTG TTCTTGACCGGGACCTTGTC
GTTCCTTCGATCAGTTGTCA TTTGAGGACTTGCGCTTTC
ATCCTCCTGGAAATCATCAA TGGAAATCCACTTGTGCACAGT
TCATGGTCACTCGATGTGAA CCATTGACGGCCAGTATTCTG
CACTGAGCAAGATGTTGCAA ACCAGTGCAATCAGGGTCTTTT
calcin.CC
GG
GC
AG
CA
TG
TC
CT
TG
AG
TA
GC
GA
AA
AC
TC
TG
TTlly identical to the control subjects.
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Osteocalcin and Endothelial Progenitors October 14, 2008:1314–25Table 2 also shows the detailed cardiac catheterization
ata in the study subjects. Based on the definition of the
roups, the ECA subjects did not have significant structural
AD, whereas the LCA patients had a mean coronary
rtery stenosis of 90%, when calculated based on coronary
rteries with at least a 50% stenosis (29,30). As expected,
arameters of epicardial and microvascular endothelial func-
ion were significantly different in the ECA subjects com-
ared with the control subjects.
low cytometry. We performed flow cytometry using an-
ibodies to the EPC markers and OCN, as described in
etail in the Methods section, and Figure 1 shows a
epresentative example of the flow analysis for CD34, KDR,
nd OCN. In preliminary experiments, we determined that
he vast majority of the CD34/KDR cells were in the
mall lymphocyte gate (Fig. 1A), as has also been noted by
ther investigators (29,31). Figures 1B and 1C show the
ow cytometry analysis for CD34/KDR cells and Figure
D shows the further analysis of these cells with the OCN
ntibody.
Figure 2 shows the analysis of peripheral blood mononu-
lear cells for the absolute counts of CD34/KDR/OCN
ells (per 100,000 counts) (Fig. 2A) as well as the percentage
f CD34/KDR cells that were OCN (Fig. 2B). As is
vident, the number of CD34/KDR/OCN cells were
ncreased (by2-fold) in the ECA patients, with somewhat
linical, Biochemical, and Cardiac Catheterization Data of the Stud
Table 2 Clinical, Biochemical, and Cardiac Catheterization Dat
Clinical data
Age, yrs
Male
BMI, kg/m2
Statin use
Diabetes
Hypertension
Smoking
Framingham score
Biochemical data
Total cholesterol, mg/dl
HDL cholesterol, mg/dl
Triglycerides, mg/dl
LDL cholesterol, mg/dl
hs-CRP, mg/l
Creatinine, mg/dl
Estimated GFR, ml/min
Cardiac catheterization data
Mean coronary artery stenosis based on all angiographically identified stenoses, %
Mean coronary artery stenosis based on coronary arteries with 50% stenosis, %
Microvascular endothelial function ( coronary blood flow to 104 mol/l acetylcho
Epicardial endothelial function ( coronary diameter to 104 mol/l acetylcholine)
Endothelium-independent microvascular function (coronary flow reserve)
ata are median (interquartile range) or n (%). *p  0.05, †p  0.01, ‡p  0.001 versus control
BMI  body mass index; ECA  early coronary atherosclerosis; GFR  glomerular filtration r
therosclerosis; LDL  low-density lipoprotein; ND  not determined.maller increases in the LCA patients. Similarly, there were c2-fold increases in the percentage of OCN of CD34/
DR cells in the ECA and LCA patients compared with
he control subjects.
To gain further insight into these changes in CD34/
DR cells in the vascular disease groups, we examined
ubpopulations of the CD34/KDR cells based on
D133 expression. As shown in Figure 3A, the absolute
umber of CD34/CD133/KDR/OCN cells were
60% higher in the ECA and LCA subjects compared with
he control subjects, but these differences did not achieve
tatistical significance. By contrast, the percentage of
CN of CD34/CD133/KDR cells were significantly
igher in the ECA subjects compared with the control
ubjects. The LCA patients also had higher percentage
evels of OCN of CD34/CD133/KDR cells as com-
ared with the control subjects, but the p value for this
ifference was 0.07.
Figure 4 shows the corresponding results for CD34/
D133/KDR/OCN cells (Fig. 4A) and percentage of
CN of CD34/CD133/KDR cells (Fig. 4B). As is
vident, there were highly significant, 5- to 7-fold increases
n these parameters in the ECA patients compared with the
ontrol subjects, and 2- to 3-fold increases in the LCA
atients compared with the control subjects.
Table 3 shows the absolute numbers of CD34/KDR,
D34/CD133/KDR, and CD34/CD133/KDR
bjects
he Study Subjects
Control
(n  21)
ECA
(n  22)
LCA
(n  29)
45 (42, 52) 50 (42, 60) 72 (63, 80)‡
5 (24) 9 (41) 26 (90)‡
28 (24, 33) 32 (25, 38) 29 (27, 33)
9 (43) 13 (59) 24 (83)†
0 (0) 0 (0) 7 (24)*
9 (43) 9 (41) 23 (79)*
4 (19) 6 (27) 18 (62)†
1.0 (2.0, 5.0) 2.5 (1.2, 6.0) 7.0 (5.0, 9.0)‡
187 (175, 206) 188 (149, 227) 154 (129, 184)†
55 (48, 67) 56 (44, 72) 45 (40, 53)†
109 (78, 168) 94 (69, 132) 105 (88, 169)
106 (98, 120) 106 (77, 133) 78 (58, 103)*
1.2 (0.5, 4.4) 1.6 (1.2, 3.8) 0.6 (0.1, 1.4)*
0.8 (0.8, 1.0) 0.9 (0.8, 1.1) 1.1 (0.9, 1.2)‡
83 (70, 95) 76 (69, 85) 69 (62, 86)*
10 (0, 20) 18 (0, 23) 70 (60, 78)‡
ND ND 90 (86, 94)
% 121.4 (62.0, 191.1) 19.1 (47.7, 17.0)‡ ND
0.4 (9.4, 2.5) 36.1 (48.6,19.4)‡ ND
2.7 (2.5, 3.4) 2.9 (2.4, 3.4) ND
L  high-density lipoprotein; hs-CRP  high sensitivity C-reactive protein; LCA  late coronaryy Su
a of t
line),
, %
.ells in the 3 groups. In contrast to the significant differ-
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October 14, 2008:1314–25 Osteocalcin and Endothelial ProgenitorsFigure 1 Example of Flow Analysis
Panel A shows the forward scatter (FSC), side scatter (SSC), and the gates used in the analysis. Panel B shows the staining with the isotype controls for the CD34- and
KDR-specific antibodies, and panel C shows the specific staining with these antibodies. Panel D shows the CD34/KDR cells stained with the osteocalcin (OCN) anti-
body. We required that 0.5% of the cells were positive with the isotype controls, and for all data reported in the article, we subtracted the signal of the isotype from
the signal due to the specific antibodies. APC  allophycocyanin; IgG  immunoglobulin G; KDR  kinase insert domain receptor.Figure 2 OCN Costaining of CD34/KDR Cells
(A) CD34/KDR/OCN cells, expressed as absolute counts per 100,000
counts, and (B) percentage of OCN of CD34/KDR cells in control subjects
(circles), patients with early coronary atherosclerosis (ECA, triangles), and in
patients with late coronary atherosclerosis (LCA, squares). *p  0.05 and
**p  0.01 compared with control subjects. Shown are the median values and
interquartile ranges. Abbreviations as in Figure 1.Figure 3 OCN Costaining of CD34/CD133/KDR Cells
(A) CD34/CD133/KDR/OCN cells, expressed as absolute counts per
100,000 counts, and (B) percentage of OCN of CD34/CD133/KDR cells
in control subjects (circles), patients with ECA (triangles), and in patients with
LCA (squares). *p  0.05 and †p  0.071 compared with control subjects.
Shown are the median values and interquartile ranges. Abbreviations as in Fig-
ures 1 and 2.
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Osteocalcin and Endothelial Progenitors October 14, 2008:1314–25nces in the cells costaining for OCN noted earlier, the
bsolute numbers of these cells did not differ significantly in
hese study subjects. The CD34/CD133/KDR cells
ere 10% lower in the LCA patients compared with the
ontrol subjects, but this difference was not statistically
ignificant.
erum RANKL, OPG, and MGP levels. Because
hanges in OPG levels have been associated with vascular
isease (32) and MGP is a known inhibitor of vascular
alcification (33), we also measured serum RANKL, OPG,
nd MGP levels in the study subjects. As shown in Table 4,
lthough serum RANKL levels did not differ in the study
ubjects, serum OPG levels were significantly higher and
erum MGP levels significantly lower in the LCA patients
ompared with the control subjects. In correlation analyses,
erum RANKL or OPG levels did not correlate with any of
he cell populations in the 3 study groups and serum MGP
evels did not correlate with the cell populations in the
ontrol or ECA patients (data not shown). However, in the
CA patients, serum MGP levels were significantly in-
ersely correlated with the absolute numbers of CD34/
D133/KDR/OCN cells (Fig. 5A), with a similar
rend seen for the percentage of OCN of CD34/
D133/KDR cells (Fig. 5B).
onfocal microscopy. Figure 6 shows evidence, using
onfocal microscopy, that each of the antibodies used in the
Figure 4 OCN Costaining of CD34/CD133/KDR Cells
(A) CD34/CD133/KDR/OCN cells, expressed as absolute counts per
100,000 counts, and (B) percentage of OCN of CD34/CD133/KDR cells
in control subjects (circles), patients with ECA (triangles), and in patients with
LCA (squares). *p  0.05, **p  0.01, and ***p  0.001 compared with
control subjects. Shown are the median values and interquartile ranges. Abbre-
viations as in Figures 1 and 2.
ifferences in CD34 Subpopulations
Table 3 Differences in CD34 Subpopulations
Control ECA LCA
CD34/KDR 181 (56, 378) 173 (70, 323) 180 (100, 240)
CD34/CD133/KDR 80 (37, 156) 77 (36, 126) 73 (48, 107)
CD34/CD133/KDR 75 (23, 200) 99 (29, 190) 98 (49, 119)
bsolute number (in counts per 100,000) of CD34/KDR, CD34/CD133/KDR, and CD34/
 D133 /KDR cells in the study subjects. Data are median (interquartile range).
KDR  kinase insert domain receptor; other abbreviations as in Table 2.tudy was binding to the surface of the cell. Note also in this
gure the relatively small size (10 m) of these cells, as
epresented by a cell positive with all 4 antibodies (CD34,
D133, KDR, and OCN).
ell culture. Although previous work from our group
14,15) and others (10–13) has shown that staining for
CN identifies cells with osteogenic potential both in bone
arrow and in peripheral blood, we next assessed whether
eripheral blood CD34 cells were capable of mineraliza-
ion in vitro. For these experiments, we used CD34 cells
solated from anonymous blood donors and found that
hen cultured on uncoated plastic plates, these cells failed
o adhere; by 21 days in osteoblast differentiation medium,
he culture plates contained no visible cells (data not
hown). Reasoning that local calcium deposition in the
asculature due to either cell death (34) or vascular micro-
alcifications might induce these cells to adhere, we next
xposed CD34 cells to an additional 2.1 mmol/l of
xtracellular Ca2 only for 5 days at the beginning of culture
days 3 to 7). Under these conditions, we found that
eripheral blood CD34 cells routinely adhered to the
erum RANKL, OPG,nd MGP Levels in the Study Subjects
Table 4 Serum RANKL, OPG,and MGP Levels in the Study Subjects
Control ECA LCA*
RANKL, pmol/l 0.02 (0.00, 0.12) 0.05 (0.00, 0.10) 0.06 (0.00, 0.21)
OPG, pmol/l 4.90 (3.20, 6.28) 4.80 (3.63, 6.69) 7.01 (4.90, 8.97)†
MGP, nmol/l 7.08 (6.07, 10.58) 8.29 (6.52, 10.18) 4.19 (3.35, 7.16)‡
ata are median (interquartile range). *Serum was available in 20 of the 29 subjects in the LCA
roup for these measurements. †p  0.05, ‡p  0.01 compared with control subjects.
OPG  osteoprotegerin; RANKL  receptor activator of nuclear factor kappa B ligand; other
bbreviations as in Tables 1 and 2.
Figure 5 Correlation With Serum MGP Levels
Correlation between serum matrix Gla protein (MGP) levels in the LCA patients
and (A) CD34/CD133/KDR/OCN cells, expressed as absolute counts
per 100,000 counts, and (B) percentage of OCN of CD34/CD133/KDR
cells. Abbreviations as in Figures 1 and 2.
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October 14, 2008:1314–25 Osteocalcin and Endothelial Progenitorslastic dishes and, when placed in osteogenic differentiation
edium for an additional 21 days, formed mineralized
odules, as assessed either by von Kossa (Fig. 7A) or alizarin
ed (Fig. 7B) staining. Note that in these assays, from days
to 28 (21 days of differentiation media), the cells were in
steoblast differentiation medium without additional cal-
ium. Because we could not obtain sufficient numbers of
ells from the patients undergoing cardiac catheterization to
pecifically isolate CD34 cells for culture, we next tested
hether PBMNCs either from normal subjects (n  3) or
atients with LCA (n  3) could be induced to mineralize
nder similar culture conditions. The PBMNCs from nor-
al subjects, who had percentages of OCN of CD34
ells of 4.2%, 9.9%, and 12.7%, respectively, did not form
ineralized colonies, without or with calcium exposure
data not shown). Of the LCA patients, PBMNCs from the
Figure 6 Confocal Microscopy of Cells
Confocal microscopy showing a cell staining with all 4 antibodies used in the stud
Shown also is a stain for nuclei (4,6-diamino-2-phenylindole or DAPI) and the merg
Figure 7 Mineralization Assays
In vitro mineralization assay of CD34 cells from an anonymous blood donor using
mononuclear cells from a patient with LCA (alizarin red stain). In these cultures, c
ferentiation medium. All images are at 4 magnification. Abbreviation as in Figureubject with the highest percentage of OCN of CD34
ells (31.2%) were able to form mineralized deposits in the
resence, but not in the absence of the brief 5-day exposure
o calcium (Fig. 7C), whereas PBMNCs from the other 2
CA patients who had lower percentages of OCN of
D34 cells (18.3% and 24.9%) failed to mineralize under
hese conditions (data not shown).
xpression of bone-related genes by CD34 cells. For
he gene expression analyses, we isolated CD34 cells using
ACS from 6 anonymous donors from the Mayo Blood
ank and compared the expression of selected bone-related
enes in these cells with the expression of the same genes in
MSCs, which are authentic osteoblast precursors (9). As
hown in Figure 8A, CD34 cells expressed significantly
igher levels of Runx2 and beta catenin than hMSCs did;
dditional bone-related genes (BMP-2, Msx-2, Notch, and
, CD34, CD133, and KDR).
ges. Abbreviations as in Figure 1.
on Kossa staining and (B) alizarin red staining, and (C) of peripheral blood
re exposed to Ca2 for 5 days followed by 21 days of culture in osteoblast dif-y (OCN
ed ima(A) v
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Osteocalcin and Endothelial Progenitors October 14, 2008:1314–25CN) were expressed at levels similar to hMSCs. The AP,
steonectin, osteopontin (OPN), MGP, Col1 alpha1 and
ol1 alpha2 mRNAs were expressed by CD34
 cells at low
evels. The stem cell marker, Nanog, was expressed at
ignificantly higher levels in CD34 compared with expres-
ion in hMSCs, whereas CD44, another stem cell marker,
as expressed at similar levels. HIF-1 alpha and the
hemokine receptor, CXCR4, both of which are involved in
oming of cells to ischemic tissues, were expressed at very
igh levels in the CD34 cells. The CD34 cells also
xpressed mRNAs for CD34 and CD45. Following in vitro
ulture of the CD34 cells (first 5 days in the presence of
a2 and than an additional 7 days in osteoblast differen-
iation medium), mRNA expression of CD34 virtually
isappeared, and CD45 mRNA was significantly decreased
Fig. 8B). Expression of OPN, a noncollagenous bone
Figure 8 Gene Expression Data
Gene expression analysis of CD34 cells from 6 anonymous blood donors. (A) Ex
marrow stromal cells (hMSCs; expression of each gene in hMSCs set at 1.0); (B)
following in vitro culture; (C) changes in expression of mRNAs for osteopontin and
alpha1 following in vitro culture in the 3 samples with the highest versus the lowe
0.001 compared with 1.0 using a 1-sample t test; †p  0.01 and ††p  0.001 c
other abbreviation as in Figure 1.atrix protein that is known to have chemoattractant rroperties (35), increased dramatically (by 36,000-fold)
ollowing culture (Fig. 8C). We also observed a 5-fold
ncrease in the expression of Col1 alpha1 under the same
ulture conditions (Fig. 8C). However, of the 6 CD34 cell
amples, the 3 with the highest expression of OCN mRNA
rior to culture significantly (by 600-fold) up-regulated
ol1 alpha1 expression, whereas the 3 with low OCN
RNA levels prior to culture did not (Fig. 8D).
bility of OCN cells to predict early coronary athero-
clerosis. To evaluate the potential utility of OCN cells as
biomarker for ECA, we performed logistic regression
odels using control and ECA subjects and tested the
bility of the cell population that differed most between the
ormal and ECA patients (CD34/CD133/KDR/
CN cells or percentage of OCN of CD34/CD133/
DR cells) to predict ECA in multivariable logistic
on of bone-related and other genes normalized to undifferentiated human bone
es in expression of messenger ribonucleic acids (mRNAs) for CD34 and CD45
alpha1 following in vitro culture; and (D) changes in mRNA expression for Col1
ession of OCN mRNA prior to culture. *p  0.05, **p  0.01, and ***p 
ed with freshly sorted CD34 cells using a 2-sample t test. N.D.  not detected;pressi
chang
Col1
st expr
omparegression models that included age and gender. In these
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October 14, 2008:1314–25 Osteocalcin and Endothelial Progenitorsge- and gender-adjusted models, both parameters were
ignificant (p  0.003 for both) predictors of ECA, with
dds ratios (95% confidence interval) of 1.9 (1.3 to 3.0) and
.0 (1.5 to 6.1) for the CD34/CD133/KDR/OCN
nd percentage of OCN of CD34/CD133/KDR
ells, respectively. Because in these models a log2 transfor-
ation of both the CD34/CD133/KDR/OCN and
he percentage of OCN of CD34/CD133/KDR cells
as used, the odds ratio represents the increase in risk
ssociated with a doubling in the percentage of these cells.
esults were similar when models were adjusted for any of
he following: statin use, diabetes, hypertension, smoking,
s-CRP, cholesterol, high-density lipoprotein, triglyceride,
ow-density lipoprotein, creatinine, and glomerular filtra-
ion rate.
Finally, we also performed ROC analyses to further assess
he ability of these cell populations to predict ECA and
laced this in the context of a similar analysis using the
urrently available marker, hs-CRP. As shown in Table 5,
oth for unadjusted and for age-adjusted models, the
ercentage of OCN of CD34/CD133/KDR cells
erformed better than hs-CRP as predictors of ECA, with
he CD34/CD133/KDR/OCN having intermediate
reas under the curve.
iscussion
e demonstrate in the present study that, compared with
ontrol subjects with normal endothelial function and no
tructural CAD, patients with ECA, characterized by cor-
nary endothelial dysfunction, or those with established
CA, characterized by severe, multivessel CAD, have a
reater percentage of CD34/KDR cells costaining for
CN. Similar increases in the percentage of OCN of
D34/CD133/KDR cells were present in the vascular
isease patients, with these subjects having even more
arked increases in the percentage of OCN of CD34/
D133/KDR cells. In addition, the absolute numbers
f CD34/CD133/KDR/OCN cells were also signif-
cantly higher in the vascular disease compared with the
ontrol subjects. These findings have potentially important
mplications for our understanding of the mechanisms of
OC Analysis
Table 5 ROC Analysis
Predictor
Unadjusted AUC
(95% CI)
Age-Adjusted
AUC (95% CI)
hs-CRP* 0.59 (0.41–0.77) 0.58 (0.40–0.76)
OCN/CD34/CD133/KDR
per 100,000*
0.78 (0.64–0.92) 0.78 (0.63–0.92)
% OCN of CD34/CD133/
KDR cells*
0.84 (0.72–0.96)† 0.84 (0.72–0.96)†
nadjusted and age-adjusted areas under the curve (AUCs) for receiver-operator characteristic
ROC) curves for prediction of ECA, using the OCN/CD34/CD133/KDR per 100,000, percent-
ge of OCN of CD34/CD133/KDR cells, or hs-CRP levels as predictors. This analysis was
one using the control and ECA patients. *log2 used; †p  0.05 versus corresponding AUC for
s-CRP.
Abbreviations as in Tables 1, 2, and 3.oronary vascular calcification and of the link between asteoporosis and vascular disease, as well as for the devel-
pment of possible new markers for vascular disease.
Although novel, our findings are nonetheless consistent
ith recent reports by Gabbasov et al. (36,37) comparing
irculating cells staining with an antibody for another
one-related protein, osteonectin, in patients with CAD com-
ared with normal subjects. In those studies, osteonectin-
ositive cells were not characterized as EPCs; however, the
nvestigators did find that osteonectin-positive cells were
ncreased in the circulation of CAD compared with control
atients. In the context of the increasing overlap between
ndothelial and osteoblastic lineages noted earlier (17–19),
ur findings and those of Gabbasov et al. (36,37) suggest
hat vascular injury or disease may be associated with
ctivation of osteogenic genes by EPCs. Because circulating
PCs may constitute the initial response to vascular injury
6,7), the expression of an osteogenic “transcriptosome” by
hese cells may promote vascular calcification rather than
ormal repair processes. Consistent with this, our gene
xpression analysis demonstrated that human circulating
D34 cells expressed a spectrum of bone-related genes,
ncluding Runx2, beta catenin, BMP-2, Msx-2, Notch, and
CN at levels similar to (or even higher than) cultured
MSCs, which are authentic osteoblast precursors (9).
Our cell culture studies using MACS-sorted CD34 cells
uggest that increases in local calcium concentrations in the
essel wall, perhaps due to cell death (34) or microcalcifi-
ations, may play a role in the adherence of circulating EPC
opulations and perhaps their differentiation toward an
steogenic phenotype. Along these lines, it is also of interest
hat, even using exposure to increased extracellular Ca2, we
ould not successfully culture mineralizing cells from un-
orted PBMNCs of normal subjects, but were able to do so
rom PBMNCs of a patient with LCA who had the highest
ercentage of OCN of CD34 cells of the 3 LCA patients
ested, which is consistent with the hypothesis that there are
ncreased concentrations of cells with mineralizing ability in
he circulation of patients with advanced atherosclerosis.
ur culture data are also consistent with a recent prelimi-
ary report by Bick et al. (38) showing that circulating
PCs from sheep and humans can be differentiated into
steoblastic cells, thus providing further support for a
ossible role for these cells in vascular calcification.
Of particular interest, OPN expression was markedly
p-regulated (by 36,000-fold) following in vitro culture in
he presence of Ca2. Osteopontin is a noncollagenous
one matrix protein produced by osteocytes, osteoblasts,
nd osteoclasts that can interact with the cell surface
eceptor, CD44 (39). However, it also appears that OPN is
ssociated with the presence and the extent of cardiovascular
isease (40), and it may serve as a chemoattractant for a
umber of cell types (35,41). Thus, production of OPN by
PCs at sites of tissue injury may modulate proliferation,
igration, and accumulation of endothelial and vascular
mooth muscle cells, thereby promoting vascular repair, but
lso perhaps initiating vascular calcification.
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Osteocalcin and Endothelial Progenitors October 14, 2008:1314–25Our cell culture studies also revealed that CD34 cells
ith higher expression of OCN mRNA prior to culture
ere the ones that up-regulated expression of Col1 alpha1
RNA following in vitro culture. Thus, the level of OCN
xpression by CD34 cells may be a predictor of the ability
f these cells to develop an osteogenic phenotype. Clearly,
urther studies are needed to address this possibility. In
ddition, studies using animal models are needed to deter-
ine whether these circulating cells lead to vascular calci-
cation or whether they initiate this process, resulting in the
ecruitment of local cells, such as vascular smooth muscle
ells or pericytes (42,43), to develop an osteogenic pheno-
ype, or both. These additional studies should help to define
he true biological role in vivo of EPC populations in
egulating the process of vascular calcification. Additionally,
urther studies using coronary histopathology are needed to
dentify whether the EPC populations differentially impact
icrocalcifications of fibrous versus lipidic origin (44) and
he outward remodeling that characterizes acute coronary
yndromes (45).
Interestingly, we also found that in the LCA patients,
D34/CD133/KDR/OCN cells were significantly
nversely correlated with serum MGP levels. Because MGP
s a known inhibitor of vascular calcification (33), these
ndings suggest a biological connection between the cell
opulations we have identified and the process of vascular
alcification that warrants further investigation. In addition,
he use of newer assays for undercarboxylated MGP (46),
hich has impaired biological function, may identify further
ssociations between this form of MGP and the cell
opulations described here and may also provide additional
isk stratification to identify patients who progress from
arly to late coronary atherosclerosis.
The current study also demonstrates for the first time that
he percentage of OCN of EPCs, particularly the CD34/
D133/KDR/OCN and percentage of OCN of
D34/CD133/KDR cells, can serve as peripheral
arkers of ECA. In fact, from a diagnostic standpoint,
hese cells outperformed the commonly used systemic
arker, hs-CRP, in ROC analyses. We recognize, however,
hat additional studies using larger numbers of subjects are
eeded to formally compare the predictive ability of these
ells with other biological markers for coronary atherosclerosis.
Although previous studies (29,47) have found associa-
ions between the numbers of EPCs defined as CD34/
DR and vascular outcomes, we did not find significant
ifferences in these cells between our study groups. The
easons for this are somewhat unclear, but may have to do
ith the specific patient populations studied, including the
act that the majority of our patients with LCA were on
tatins, which are known to increase circulating EPCs (48).
n this context, our findings suggest that the addition of
CN as a biomarker to CD34/KDR or CD34/
D133/KDR cells may be of use in predicting cardio-
ascular outcomes, and prospective studies addressing this
ossibility are needed.onclusions
ur findings demonstrate that a higher number and per-
entage of circulating cell populations containing EPCs
ostain for OCN in patients with early or late coronary
therosclerosis compared with control subjects with normal
ndothelial function and no structural CAD. These data
uggest that the activation of an osteogenic program by
PCs may play a role in the response to vascular injury and
ontribute to vascular calcification, as opposed to noncalci-
ying vascular repair. Additionally, the same proinflamma-
ory factors involved in the pathogenesis of osteoporosis
ay lead to the expression of an osteogenic phenotype by
ndothelial lineage cells, providing a potential mechanism
or the link between osteoporosis and vascular calcifications.
inally, our finding that the number of CD34/CD133/
DR/OCN cells and percentage of OCN of CD34/
D133/KDR cells can predict coronary atherosclerosis
uggests that these (or similar) cell populations may hold
romise as novel markers for vascular disease.
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